查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2143536

Fluoroquinolones抗生素市場：全球市場預測，2026-2032年

Fluoroquinolone Antibiotics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Fluoroquinolones抗生素市場將成長至 99.8 億美元，複合年成長率為 6.67%。

主要市場統計數據
基準年 2025 63.5億美元
預計年份：2026年 67.1億美元
預測年份 2032 99.8億美元
複合年成長率 (%) 6.67%

Fluoroquinolones抗生素：概述

Fluoroquinolones抗生素是頻譜抗生素，用於治療某些細菌感染，包括尿道感染、胃腸道感染疾病、呼吸道感染疾病、伴隨併發症的組織感染疾病。隨著治療價值與抗生素抗藥性、副作用和合理用藥感染疾病之間權衡的日益凸顯，其臨床應用也日益明確。因此，其使用模式會因當地疾病負擔、處方規定、診斷能力以及獲得替代抗生素的途徑而有所不同。

合理使用和安全性正在改變Fluoroquinolones抗生素的使用方式。

目前，抗菌藥物的使用正從廣泛、經驗性的處方轉向基於微生物檢測和當地藥敏數據的更有針對性的治療。監管資訊和臨床指南強調了此類藥物可能引起的嚴重副作用，包括肌腱、神經、中樞神經系統、血糖調節和主要血管受損。同時，抗菌藥物管理計畫也日益限制此類藥物的使用，僅在獲益大於風險的情況下使用。因此，醫院抗菌藥物委員會、電子處方管理系統和更新的治療方案在藥物使用決策中發揮越來越重要的作用。

人工智慧可以提高藥物的選擇、監測和合理使用。

人工智慧可以透過識別高風險患者（例如發生Fluoroquinolones感染疾病和不利事件的患者）、改進微生物檢測結果的解讀以及幫助臨床醫生使處方符合機構指南，從而輔助氟喹諾酮類抗生素的管理。機器學習系統還可以透過整合檢查室數據、處方數據和流行病學數據來支持抗生素抗藥性監測。其價值取決於具有代表性的資料集、透明的檢驗、人工監督、網路安全以及防止不恰當經驗性治療自動化的安全措施。

區域差異反映了抵抗力、監管和診斷能力。

北美地區擁有完善的抗生素合理使用基礎設施、廣泛的安全監測體系，並高度重視以指引為基礎的處方。歐洲則將協調一致的抗藥性監測與部分地區的限制性措施結合。亞太地區的醫療保健系統高度多元化，既有擁有先進診斷技術的地區，也有經驗性治療仍然至關重要的地區。拉丁美洲仍在努力平衡感染疾病控制需求與檢測能力差異以及處方管理實踐的多樣性。中東地區在轉診醫院容量、人口流動和區域抗藥性模式等方面存在差異，而非洲則在診斷、藥物取得、監測以及嚴重細菌性疾病負擔方面面臨顯著差異。

不同經濟和製度群體對合理使用抗生素的成熟度有差異。

由於東南亞國協在監管執法、檢測實驗室資源和抗菌素抗藥性監測方面存在顯著差異，區域合作至關重要。金磚國家成員國在醫療資源、國內生產能力和處方環境方面也存在顯著差異。歐盟雖然受益於通用的監測和政策機制，但各國之間的執行情況仍不盡相同。七國集團（G7）國家通常擁有健全的藥物安全監測和合理用藥管理體系，而海灣合作理事會（GCC）國家則面臨著資源豐富的都市區醫療體係以及患者和醫護人員大規模跨境流動的雙重挑戰。北約成員國的醫療體系並非同質，但抗菌素抗藥性問題日益被視為國防和民用醫療體系中亟待解決的挑戰。

各國優先事項差異很大，從取得醫療資源和診斷到採取抗藥性應對措施，不一而足。

澳洲、加拿大、法國、德國、義大利、日本、韓國、英國、英國和美國普遍優先考慮合理用藥、安全監測和抗生素抗藥性監測，但各國在處方指南和醫療保險報銷制度方面存在差異。中國和印度由於其龐大且多元化的醫療體系、診斷可及性的差異以及抗生素使用的複雜性，在全球抗擊抗藥性工作中發揮核心作用。巴西和墨西哥仍在努力應對可及性差異、監管實施和檢測能力方面的挑戰。俄羅斯面臨在其地域遼闊的醫療體系中協調處方規範和監測工作的必要性。在上述所有國家，治療決策應盡可能基於細菌培養結果、當地藥敏數據、患者個別風險評估和已批准的適應症。

教師的首要任務：讓合理使用變得簡單易行且可衡量。

產業領導者應投資於快速診斷、可靠的藥敏試驗以及能夠將處方與治療結果和抗藥性趨勢聯繫起來的互通監測系統。藥物管理工具應將已批准的適應症、禁忌症檢查、藥物交互作用警告、基於腎功能的劑量指南以及自動審核點整合到臨床工作流程中。各機構應加強不利事件識別的教育，擴大審核和回饋機制，並使用臨床結果而非僅使用處方劑量來評估介入措施。雖然與公共衛生機構的合作可以提高數據質量，但負責任的人工智慧管治必須要求檢驗、可解釋性、偏差監控和臨床醫生課責。

調查方法：基於證據的臨床和政策訊號整合

本執行摘要整合了與Fluoroquinolones抗生素相關的已驗證的檢驗，包括監管安全資訊、臨床指南、抗菌素抗藥性監測、同行評審研究以及來自公共醫療系統和公共衛生機構的官方出版刊物。研究結果按全球趨勢、技術影響、地區、經濟和機構群體以及具體國家進行分類。本分析不包括市場估算、預測、市場佔有率和公司特定聲明，除非數據統一，否則區域差異被視為與具體情況相關，不具有直接可比性。

結論：透過有針對性和負責任的使用來維持臨床價值。

儘管Fluoroquinolones抗生素在臨床上仍然十分重要，但其應用正變得越來越局限。抗藥性、安全性問題、監管要求以及診斷工具的改進，正促使醫療系統轉向更有針對性的處方和更全面的追蹤。將可靠的診斷、規範的合理用藥、高品質的監測和精心管理的人工智慧相結合的醫療機構，能夠保護患者預後，減少不必要的藥物暴露，並維持這些抗生素的療效。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章Fluoroquinolones抗生素市場：依產品類型分類

  • Ciprofloxacin
    • 品牌
    • 非專利的
  • levofloxacin
    • 品牌
    • 非專利的
  • 莫西沙星
    • 品牌
    • 非專利的
  • 諾氟沙星
    • 品牌
    • 非專利的
  • 氧氟沙星
    • 品牌
    • 非專利的

第8章：Fluoroquinolones抗生素市場：依給藥途徑分類

  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈

第9章：Fluoroquinolones抗生素市場：以劑型分類

  • 注射藥物
  • 懸浮液
  • 藥片

第10章：Fluoroquinolones抗生素市場：以最終用戶分類

  • 門診部
  • 診所
  • 家庭醫療保健
  • 醫院

第11章：Fluoroquinolones抗生素市場：依通路分類

  • 醫院藥房
    • 私立醫院的藥房
    • 公立醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第12章Fluoroquinolones抗生素市場：依應用領域分類

  • 胃腸道感染疾病
  • 呼吸道感染疾病
    • 社區傳播
    • 院內感染
  • 皮膚和軟組織感染疾病
  • 尿道感染
    • 伴隨併發症的尿道感染
    • 單純性尿道感染

第13章：Fluoroquinolones抗生素市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章Fluoroquinolones抗生素市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章Fluoroquinolones抗生素市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc
  • Astellas Pharma Inc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd
  • Mylan NV（Viatris Inc）
  • Novartis AG
  • Organon & Co
  • Pfizer Inc
  • Ranbaxy Laboratories Ltd
  • Sandoz International GmbH
  • Sanofi SA
  • Shanghai Fosun Pharmaceutical（Group）Co Ltd
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Limited

第18章 主要專家

Product Code: MRR-9C4233EE7D30

The Fluoroquinolone Antibiotics Market is projected to grow by USD 9.98 billion at a CAGR of 6.67% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.35 billion
Estimated Year [2026] USD 6.71 billion
Forecast Year [2032] USD 9.98 billion
CAGR (%) 6.67%

Fluoroquinolone Antibiotics: Executive Overview

Fluoroquinolone antibiotics are broad-spectrum medicines used against selected bacterial infections, including urinary, gastrointestinal, respiratory, and complicated tissue infections. Their clinical role is increasingly defined by the need to balance therapeutic value with antimicrobial resistance, adverse-effect risk, and stewardship requirements. Use patterns therefore vary according to local disease burden, prescribing controls, diagnostic capacity, and access to alternative antibiotics.

Stewardship and Safety Are Reshaping Fluoroquinolone Use

The landscape is shifting from broad empirical prescribing toward more targeted treatment supported by microbiological testing and local susceptibility data. Regulatory communications and clinical guidance have emphasized potentially serious adverse effects involving tendons, nerves, the central nervous system, glucose regulation, and major blood vessels, while stewardship programs increasingly reserve these medicines for situations in which benefits outweigh risks. Hospital antimicrobial committees, electronic prescribing controls, and updated treatment protocols are consequently becoming more influential in determining utilization.

Artificial Intelligence Strengthens Selection, Surveillance, and Stewardship

Artificial intelligence can support fluoroquinolone management by identifying patients at elevated risk of resistant infection or adverse events, improving interpretation of microbiology results, and helping clinicians align prescriptions with institutional guidelines. Machine-learning systems can also assist with antimicrobial-resistance surveillance by combining laboratory, prescribing, and epidemiological data. Their value depends on representative datasets, transparent validation, human oversight, cybersecurity, and safeguards against automating inappropriate empirical treatment.

Regional Differences Reflect Resistance, Regulation, and Diagnostic Capacity

North America is characterized by mature stewardship infrastructure, extensive safety monitoring, and strong emphasis on guideline-concordant prescribing. Europe combines coordinated resistance surveillance with restrictive approaches in several settings. Asia-Pacific includes highly diverse healthcare systems, from advanced diagnostics to areas where empirical access remains important. Latin America continues to balance infectious-disease needs with uneven laboratory capacity and variable enforcement of prescription controls. The Middle East shows differences linked to referral-hospital capacity, migration, and local resistance patterns, while Africa faces substantial variation in diagnostics, medicine access, surveillance, and the burden of serious bacterial disease.

Economic and Institutional Groups Show Uneven Stewardship Maturity

ASEAN markets differ considerably in regulatory enforcement, laboratory access, and antimicrobial-resistance surveillance, making regional coordination important. BRICS members span major differences in health-system resources, domestic production capabilities, and prescribing environments. The European Union benefits from shared surveillance and policy mechanisms, although national implementation remains varied. G7 countries generally have strong pharmacovigilance and stewardship systems, while GCC states combine well-resourced urban care with substantial cross-border patient and workforce movement. NATO members are not a uniform healthcare group, but defense and civilian systems increasingly recognize antimicrobial resistance as a preparedness concern.

Country-Level Priorities Range from Access and Diagnostics to Resistance Control

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally emphasize stewardship, safety surveillance, and antimicrobial-resistance monitoring, with national differences in prescribing guidance and reimbursement. China and India are central to global resistance-control efforts because of their large and diverse healthcare systems, varied diagnostic access, and substantial antibiotic-use complexity. Brazil and Mexico continue to address uneven access, regulatory implementation, and laboratory capacity. Russia faces the need to align prescribing practices and surveillance across a geographically extensive system. Across all listed countries, treatment decisions should be guided by culture results where feasible, local susceptibility data, patient-specific risk assessment, and approved indications.

Priorities for Leaders: Make Appropriate Use Easier and Measurable

Industry leaders should invest in rapid diagnostics, robust susceptibility testing, and interoperable surveillance that links prescribing with outcomes and resistance trends. Stewardship tools should embed approved indications, contraindication checks, interaction alerts, renal-dose guidance, and automatic review points into clinical workflows. Organizations should strengthen education on adverse-event recognition, expand audit-and-feedback programs, and evaluate interventions using clinical outcomes rather than prescription volume alone. Partnerships with public-health authorities can improve data quality, while responsible AI governance should require validation, explainability, bias monitoring, and clinician accountability.

Methodology: Evidence-Based Synthesis of Clinical and Policy Signals

This executive summary synthesizes verified public evidence relevant to fluoroquinolone antibiotics, including regulatory safety communications, clinical guidelines, antimicrobial-resistance surveillance, peer-reviewed research, and official health-system or public-health publications. Findings are organized by global shifts, technology implications, regions, economic and institutional groups, and specified countries. The analysis avoids market estimates, forecasts, market shares, and company-specific claims, and treats differences between geographies as context-dependent rather than directly comparable without harmonized data.

Conclusion: Preserve Clinical Value Through Targeted, Accountable Use

Fluoroquinolones remain clinically important, but their role is increasingly selective. Resistance, safety concerns, regulatory expectations, and improved diagnostic options are pushing healthcare systems toward targeted prescribing and stronger follow-up. Leaders that combine reliable diagnostics, disciplined stewardship, high-quality surveillance, and carefully governed AI can protect patient outcomes while reducing avoidable exposure and preserving the effectiveness of these antibiotics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Fluoroquinolone Antibiotics Market, by Product Type

  • 7.1. Introduction
  • 7.2. Ciprofloxacin
    • 7.2.1. Branded
    • 7.2.2. Generic
  • 7.3. Levofloxacin
    • 7.3.1. Branded
    • 7.3.2. Generic
  • 7.4. Moxifloxacin
    • 7.4.1. Branded
    • 7.4.2. Generic
  • 7.5. Norfloxacin
    • 7.5.1. Branded
    • 7.5.2. Generic
  • 7.6. Ofloxacin
    • 7.6.1. Branded
    • 7.6.2. Generic

8. Fluoroquinolone Antibiotics Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
    • 8.3.1. Intramuscular
    • 8.3.2. Intravenous

9. Fluoroquinolone Antibiotics Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Injection
  • 9.3. Suspension
  • 9.4. Tablet

10. Fluoroquinolone Antibiotics Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Care Settings
  • 10.3. Clinics
  • 10.4. Home Healthcare
  • 10.5. Hospitals

11. Fluoroquinolone Antibiotics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
    • 11.2.1. Private Hospital Pharmacy
    • 11.2.2. Public Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy
    • 11.4.1. Chain Pharmacy
    • 11.4.2. Independent Pharmacy

12. Fluoroquinolone Antibiotics Market, by Application

  • 12.1. Introduction
  • 12.2. Gastrointestinal Infection
  • 12.3. Respiratory Infection
    • 12.3.1. Community Acquired
    • 12.3.2. Hospital Acquired
  • 12.4. Skin And Soft Tissue Infection
  • 12.5. Urinary Tract Infection
    • 12.5.1. Complicated Uti
    • 12.5.2. Uncomplicated Uti

13. Fluoroquinolone Antibiotics Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Fluoroquinolone Antibiotics Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Fluoroquinolone Antibiotics Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc
  • 17.2. Astellas Pharma Inc
  • 17.3. Aurobindo Pharma Limited
  • 17.4. Bayer AG
  • 17.5. Cipla Limited
  • 17.6. Dr. Reddy's Laboratories Ltd
  • 17.7. Eli Lilly and Company
  • 17.8. Fresenius Kabi AG
  • 17.9. GlaxoSmithKline plc
  • 17.10. Hikma Pharmaceuticals PLC
  • 17.11. Johnson & Johnson
  • 17.12. Lupin Limited
  • 17.13. Macleods Pharmaceuticals Ltd
  • 17.14. Mylan N.V. (Viatris Inc)
  • 17.15. Novartis AG
  • 17.16. Organon & Co
  • 17.17. Pfizer Inc
  • 17.18. Ranbaxy Laboratories Ltd
  • 17.19. Sandoz International GmbH
  • 17.20. Sanofi S.A.
  • 17.21. Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • 17.22. Sun Pharmaceutical Industries Ltd
  • 17.23. Takeda Pharmaceutical Company Limited
  • 17.24. Teva Pharmaceutical Industries Ltd
  • 17.25. Zydus Lifesciences Limited

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Fluoroquinolone Antibiotics Market, Years Considered for the Study
  • FIGURE 2. Global Fluoroquinolone Antibiotics Market, Research Design
  • FIGURE 3. Global Fluoroquinolone Antibiotics Market, Research Framework
  • FIGURE 4. Global Fluoroquinolone Antibiotics Market, Data Triangulation
  • FIGURE 5. Global Fluoroquinolone Antibiotics Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Fluoroquinolone Antibiotics Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Fluoroquinolone Antibiotics Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 11. Global Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Fluoroquinolone Antibiotics Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global Fluoroquinolone Antibiotics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 15. Global Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Fluoroquinolone Antibiotics Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 17. Global Fluoroquinolone Antibiotics Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Fluoroquinolone Antibiotics Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Fluoroquinolone Antibiotics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Fluoroquinolone Antibiotics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Fluoroquinolone Antibiotics Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Fluoroquinolone Antibiotics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Fluoroquinolone Antibiotics Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Fluoroquinolone Antibiotics Market Segmentation & Coverage
  • TABLE 2. Global Fluoroquinolone Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Ciprofloxacin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Ciprofloxacin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Ciprofloxacin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Branded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Branded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Branded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Levofloxacin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Levofloxacin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Levofloxacin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Branded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Branded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Branded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Moxifloxacin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Moxifloxacin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Moxifloxacin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Branded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Branded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Branded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Norfloxacin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Norfloxacin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Norfloxacin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Branded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Branded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Branded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Ofloxacin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Ofloxacin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Ofloxacin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Branded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Branded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Branded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 50. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Parenteral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Parenteral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Parenteral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 63. Global Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Suspension Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Suspension Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Suspension Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 73. Global Ambulatory Care Settings Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Ambulatory Care Settings Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Ambulatory Care Settings Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 84. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 85. Global Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 86. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global Private Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Global Private Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. Global Private Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 92. Global Public Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Global Public Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. Global Public Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 95. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 98. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 101. Global Chain Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Global Chain Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. Global Chain Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 104. Global Independent Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Global Independent Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. Global Independent Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 107. Global Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 108. Global Gastrointestinal Infection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 109. Global Gastrointestinal Infection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 110. Global Gastrointestinal Infection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 111. Global Respiratory Infection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 112. Global Respiratory Infection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 113. Global Respiratory Infection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 114. Global Community Acquired Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Global Community Acquired Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. Global Community Acquired Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 117. Global Hospital Acquired Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 118. Global Hospital Acquired Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 119. Global Hospital Acquired Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 120. Global Skin And Soft Tissue Infection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. Global Skin And Soft Tissue Infection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 122. Global Skin And Soft Tissue Infection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 123. Global Urinary Tract Infection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 124. Global Urinary Tract Infection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. Global Urinary Tract Infection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 126. Global Complicated Uti Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 127. Global Complicated Uti Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 128. Global Complicated Uti Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 129. Global Uncomplicated Uti Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 130. Global Uncomplicated Uti Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 131. Global Uncomplicated Uti Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 132. Global Fluoroquinolone Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 133. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 134. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 135. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 136. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 137. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 138. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 139. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 140. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 141. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 142. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 143. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 144. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 145. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 146. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 147. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 148. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 149. Asia-Pacific Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 150. North America Fluoroquinolone Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 151. North America Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 152. North America Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 153. North America Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 154. North America Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 155. North America Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 156. North America Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 157. North America Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 158. North America Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 159. North America Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 160. North America Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 161. North America Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 162. North America Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 163. North America Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 164. North America Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 165. North America Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 166. North America Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 167. Latin America Fluoroquinolone Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 168. Latin America Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 169. Latin America Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 170. Latin America Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 171. Latin America Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 172. Latin America Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 173. Latin America Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 174. Latin America Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 175. Latin America Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 176. Latin America Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 177. Latin America Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 178. Latin America Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 179. Latin America Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 180. Latin America Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 181. Latin America Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 182. Latin America Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 183. Latin America Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 184. Europe Fluoroquinolone Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 185. Europe Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 186. Europe Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 187. Europe Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 188. Europe Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 189. Europe Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 190. Europe Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 191. Europe Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 192. Europe Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 193. Europe Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 194. Europe Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 195. Europe Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 196. Europe Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 197. Europe Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 198. Europe Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 199. Europe Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 200. Europe Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 201. Middle East Fluoroquinolone Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 202. Middle East Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 203. Middle East Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 204. Middle East Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 205. Middle East Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 206. Middle East Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 207. Middle East Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 208. Middle East Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 209. Middle East Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 210. Middle East Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 211. Middle East Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 212. Middle East Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 213. Middle East Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 214. Middle East Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 215. Middle East Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 216. Middle East Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 217. Middle East Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 218. Africa Fluoroquinolone Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 219. Africa Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 220. Africa Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 221. Africa Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 222. Africa Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 223. Africa Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 224. Africa Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 225. Africa Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 226. Africa Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 227. Africa Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 228. Africa Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 229. Africa Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 230. Africa Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 231. Africa Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 232. Africa Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 233. Africa Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 234. Africa Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 235. Global Fluoroquinolone Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 236. ASEAN Fluoroquinolone Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 237. ASEAN Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 238. ASEAN Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 239. ASEAN Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 240. ASEAN Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 241. ASEAN Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 242. ASEAN Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 243. ASEAN Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 244. ASEAN Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 245. ASEAN Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 246. ASEAN Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 247. ASEAN Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 248. ASEAN Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 249. ASEAN Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 250. ASEAN Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 251. ASEAN Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 252. ASEAN Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 253. GCC Fluoroquinolone Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 254. GCC Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 255. GCC Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 256. GCC Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 257. GCC Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 258. GCC Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 259. GCC Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 260. GCC Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 261. GCC Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 262. GCC Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 263. GCC Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 264. GCC Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 265. GCC Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 266. GCC Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 267. GCC Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 268. GCC Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 269. GCC Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 270. European Union Fluoroquinolone Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 271. European Union Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 272. European Union Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 273. European Union Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 274. European Union Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 275. European Union Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 276. European Union Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 277. European Union Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 278. European Union Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 279. European Union Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 280. European Union Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 281. European Union Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 282. European Union Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 283. European Union Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 284. European Union Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 285. European Union Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 286. European Union Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 287. BRICS Fluoroquinolone Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 288. BRICS Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 289. BRICS Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 290. BRICS Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 291. BRICS Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 292. BRICS Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 293. BRICS Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 294. BRICS Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 295. BRICS Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 296. BRICS Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 297. BRICS Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 298. BRICS Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 299. BRICS Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 300. BRICS Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 301. BRICS Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 302. BRICS Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 303. BRICS Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 304. G7 Fluoroquinolone Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 305. G7 Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 306. G7 Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 307. G7 Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 308. G7 Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 309. G7 Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 310. G7 Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 311. G7 Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 312. G7 Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 313. G7 Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 314. G7 Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 315. G7 Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 316. G7 Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 317. G7 Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 318. G7 Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 319. G7 Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 320. G7 Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 321. NATO Fluoroquinolone Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 322. NATO Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 323. NATO Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 324. NATO Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 325. NATO Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 326. NATO Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 327. NATO Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 328. NATO Fluoroquinolone Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 329. NATO Fluoroquinolone Antibiotics Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 330. NATO Fluoroquinolone Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 331. NATO Fluoroquinolone Antibiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 332. NATO Fluoroquinolone Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 333. NATO Fluoroquinolone Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 334. NATO Fluoroquinolone Antibiotics Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 335. NATO Fluoroquinolone Antibiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 336. NATO Fluoroquinolone Antibiotics Market Size, by Respiratory Infection, 2017-2032 (USD Million)
  • TABLE 337. NATO Fluoroquinolone Antibiotics Market Size, by Urinary Tract Infection, 2017-2032 (USD Million)
  • TABLE 338. Global Fluoroquinolone Antibiotics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 339. United States Fluoroquinolone Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 340. United States Fluoroquinolone Antibiotics Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 341. United States Fluoroquinolone Antibiotics Market Size, by Ciprofloxacin, 2017-2032 (USD Million)
  • TABLE 342. United States Fluoroquinolone Antibiotics Market Size, by Levofloxacin, 2017-2032 (USD Million)
  • TABLE 343. United States Fluoroquinolone Antibiotics Market Size, by Moxifloxacin, 2017-2032 (USD Million)
  • TABLE 344. United States Fluoroquinolone Antibiotics Market Size, by Norfloxacin, 2017-2032 (USD Million)
  • TABLE 345. United States Fluoroquinolone Antibiotics Market Size, by Ofloxacin, 2017-2032 (USD Million)
  • TABLE 346. United States Fluoroquinolone Antibiotics Market Size, by Route Of Administration,